TB-500: reading the thymosin beta-4 fragment straight

TB-500 is a synthetic peptide that copies the working part of a much larger natural protein called thymosin beta-4. Rather than reproduce the whole 43-residue protein, chemists isolated the short stretch responsible for one of its key jobs, binding actin, and acetylated one end to slow breakdown. The result is a compact seven-residue fragment that laboratories study in cell-migration and tissue-repair models. It is worth being precise here: TB-500 is a fragment, not the full protein, and the two are not interchangeable even though the names get blurred in marketing copy.

For laboratory research use only. Not for human or veterinary use.

What the molecule actually is

TB-500 is an N-terminally acetylated heptapeptide with the sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, written LKKTETQ in one-letter code. That short run corresponds to the actin-binding motif of thymosin beta-4, the segment that lets the parent protein grab and hold monomeric actin. The acetyl cap on the N-terminus is not cosmetic. It removes a charged amino group and makes the fragment more resistant to the enzymes that trim peptides from that end, which is part of why the acetylated version is the one sold for research.

The free-base molecular weight is about 889 g/mol. Because it is a small, water-soluble peptide of standard L-amino acids, it reconstitutes easily and behaves predictably in the lab. The distinction to keep straight is scale. Thymosin beta-4 is a 43-residue protein with several functions, while TB-500 is a seven-residue slice chosen for one of them. A supplier certificate of analysis should make clear which material is actually in the vial, because the two are routinely confused.

Verified molecule

• Sequence (1-letter): LKKTETQ (supplied as the N-acetylated fragment, Ac-LKKTETQ)
• Molecular formula: C38H68N10O14
• Molecular weight: 889.0 g/mol (free base)
• CAS number: 885340-08-9
• Class: N-acetylated heptapeptide, thymosin beta-4 actin-binding fragment

What the literature examines

The mechanistic anchor is actin. Thymosin beta-4 is the main G-actin-sequestering protein in many cells, meaning it holds a reserve pool of unpolymerised actin monomers and releases them when a cell needs to build filaments. Actin turnover sits at the centre of cell movement, so the actin-binding fragment is studied for its influence on how cells migrate, a process that matters in tissue repair, blood-vessel formation and remodelling of the extracellular matrix.

In practice the published work spans wound-repair models, corneal and cardiac injury models in animals, and cell-culture assays of migration and angiogenesis. A widely cited 2005 review by Goldstein, Hannappel and Kleinman framed thymosin beta-4 as an actin-sequestering protein that moonlights to repair injured tissue, and much of the TB-500 literature builds on that framing. As with BPC-157, the recurring caution is that the strongest signals come from animals and cultured cells, not from controlled human study.

One reason the fragment attracts attention is efficiency. If most of thymosin beta-4's actin activity lives in seven residues, then a short synthetic peptide is far cheaper to make and easier to characterise than the full protein, while still probing the same pathway. That logic is sound, but it also means results obtained with the fragment cannot be assumed to reproduce every action of the intact protein, which carries other functional regions beyond the actin motif.

A quick word on why actin is the crux. Cell migration depends on constant assembly and disassembly of actin filaments at the leading edge of a moving cell. A protein that sequesters monomeric actin sets the size of the reserve pool feeding that process, so anything touching that pool can, in principle, change how readily cells move. That is the bridge between a small actin-binding fragment and the repair-oriented endpoints the literature keeps returning to: wound closure, vessel growth and matrix remodelling all trace back to cells moving into a damaged area and rebuilding it.

Where it came from

Thymosin beta-4 itself was first isolated from the thymus in the 1980s, and its actin-binding role was worked out over the following decade. TB-500 emerged as researchers narrowed in on the specific fragment that carried the actin activity, giving a smaller, easier-to-synthesise molecule for study. The seven-residue design is deliberate: it keeps the functional motif while dropping the bulk of the protein that is harder to make and less relevant to the actin question.

Honest limitations

The evidence pattern mirrors other repair peptides. Most data are preclinical, and the jump from a rodent injury model to a human outcome is not supported by controlled trials in the peer-reviewed record. There is also real confusion in the market between TB-500 and full-length thymosin beta-4, and some material sold under one name is closer to the other. That matters for anyone trying to reproduce a published result, because the two molecules are not equivalent and will not behave the same way in an assay.

It is also easy to over-read the animal work. Encouraging results in a corneal or cardiac injury model are a starting point, not an endpoint, and the mechanisms that make actin turnover matter in a dish can be confounded by many other factors in a whole organism. The honest summary is that TB-500 sits on a plausible mechanistic foundation with a scattered preclinical record on top of it, and the record has not yet been consolidated by the kind of rigorous, independent work that would let anyone speak confidently about outcomes.

Analytical caveats apply as well. Because the fragment is short and the market is fragmented, purity and identity vary between suppliers. Mass spectrometry and a lot-specific certificate of analysis are the reliable way to know what is in a vial, especially given how easily the labels TB-500 and thymosin beta-4 get swapped. For reproducible work, confirming the acetylation and the exact sequence is worth the effort up front.

Common questions

What is TB-500?

It is a synthetic, acetylated seven-residue peptide (Ac-LKKTETQ) that copies the actin-binding motif of the protein thymosin beta-4. In research it is studied for effects on actin dynamics and cell migration, mainly in animal and cell-culture models.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is the full 43-residue protein with several roles, while TB-500 is a short fragment representing only its actin-binding region. They are related but chemically and functionally distinct, and vials should be labelled clearly for which one they contain.

How is it stored?

The lyophilised peptide is generally kept frozen, dry and out of light, with reconstituted solution held cold and used promptly. Exact stability depends on buffer and salt form, so the lot certificate of analysis is the authority rather than a general figure.

References

1. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.